Aprea Therapeutics (APRE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a $20.00 price target.
Joseph Pantginis has given his Buy rating due to a combination of factors related to Aprea Therapeutics’ promising oncology pipeline that focuses on DNA Damage Response (DDR). The company’s presentation at AACR 2024 included updates on several compounds, notably APR-1051, a next-generation inhibitor of WEE1 kinase, and ATRN-119, a novel macrocyclic ATR inhibitor. Pantginis acknowledged the positive preliminary data from the ongoing study of ATRN-119 in patients with advanced solid tumors, citing its safety, tolerability, and initial signs of clinical benefit. Additionally, the FDA’s recent clearance of the IND application for APR-1051 supports the company’s strategy for the upcoming biomarker-driven Phase 1 trial, further reinforcing the Buy recommendation.
Furthermore, Pantginis’s rating was bolstered by the introduction of ATRN-333, Aprea Therapeutics’ latest addition to its pipeline, presenting preclinical data demonstrating its potential in treating glioblastoma. The reported synergistic effects of ATRN-333 when combined with lomustine, along with its intracranial retention and tolerability in animal models, suggest a promising chemosensitizer role for ATRN-333 and other macrocyclic ATR inhibitors. This expansion of Aprea’s pipeline and the strategic approach to clinical development contribute to the Buy rating, signifying confidence in the company’s long-term growth prospects and its contributions to targeted cancer therapies.
In another report released on March 27, Wedbush also assigned a Buy rating to the stock with a $11.00 price target.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Aprea Therapeutics (APRE) Company Description:
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded in 2002 and is headquartered in Boston, MA.
Read More on APRE:
- Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
- Aprea Therapeutics files to sell 4.39M shares of common stock for holders
- Aprea Therapeutics price target raised to $11 from $9 at Wedbush
- Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
- Aprea Therapeutics sees cash runway into 3Q25
